Molecular Partners Ag Stock Shares Outstanding
| MOLN Stock | USD 5.82 0.01 0.17% |
Molecular Partners AG fundamentals help investors to digest information that contributes to Molecular Partners' financial success or failures. It also enables traders to predict the movement of Molecular Stock. The fundamental analysis module provides a way to measure Molecular Partners' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Molecular Partners stock.
As of the 1st of December 2024, Common Stock Shares Outstanding is likely to drop to about 26 M. Molecular | Shares Outstanding |
Molecular Partners AG Company Shares Outstanding Analysis
Molecular Partners' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Molecular Partners Shares Outstanding | 36.84 M |
Most of Molecular Partners' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Molecular Partners AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Molecular Shares Outstanding Driver Correlations
Understanding the fundamental principles of building solid financial models for Molecular Partners is extremely important. It helps to project a fair market value of Molecular Stock properly, considering its historical fundamentals such as Shares Outstanding. Since Molecular Partners' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Molecular Partners' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Molecular Partners' interrelated accounts and indicators.
Click cells to compare fundamentals
Molecular Shares Outstanding Historical Pattern
Today, most investors in Molecular Partners Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Molecular Partners' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Molecular Partners shares outstanding as a starting point in their analysis.
Molecular Partners Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Molecular Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Molecular Partners AG has 36.84 M of shares currently outstending. This is 79.6% lower than that of the Biotechnology sector and 65.53% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 93.56% higher than that of the company.
Molecular Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecular Partners' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Molecular Partners could also be used in its relative valuation, which is a method of valuing Molecular Partners by comparing valuation metrics of similar companies.Molecular Partners is currently under evaluation in shares outstanding category among its peers.
Molecular Partners Current Valuation Drivers
We derive many important indicators used in calculating different scores of Molecular Partners from analyzing Molecular Partners' financial statements. These drivers represent accounts that assess Molecular Partners' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Molecular Partners' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 548.7M | 387.4M | 552.5M | 200.0M | 112.7M | 107.1M | |
| Enterprise Value | 417.3M | 288.4M | 486.7M | 116.9M | 49.1M | 46.6M |
Molecular Partners ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Molecular Partners' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Molecular Partners' managers, analysts, and investors.Environmental | Governance | Social |
Molecular Fundamentals
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (21.42) % | ||||
| Current Valuation | 57.44 M | ||||
| Shares Outstanding | 36.84 M | ||||
| Shares Owned By Institutions | 5.31 % | ||||
| Number Of Shares Shorted | 57.95 K | ||||
| Price To Earning | 1.85 X | ||||
| Price To Book | 1.36 X | ||||
| Price To Sales | 36.07 X | ||||
| Revenue | 7.04 M | ||||
| Gross Profit | 138.85 M | ||||
| EBITDA | (59.53 M) | ||||
| Net Income | (61.98 M) | ||||
| Cash And Equivalents | 267.13 M | ||||
| Cash Per Share | 8.22 X | ||||
| Total Debt | 3.65 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.37 X | ||||
| Book Value Per Share | 4.18 X | ||||
| Cash Flow From Operations | (59.01 M) | ||||
| Short Ratio | 1.61 X | ||||
| Earnings Per Share | (2.14) X | ||||
| Target Price | 9.33 | ||||
| Number Of Employees | 167 | ||||
| Beta | 0.54 | ||||
| Market Capitalization | 216.52 M | ||||
| Total Asset | 198.35 M | ||||
| Retained Earnings | (191.75 M) | ||||
| Working Capital | 178.04 M | ||||
| Net Asset | 198.35 M |
About Molecular Partners Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Molecular Partners AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecular Partners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecular Partners AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Molecular Partners
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Molecular Partners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will appreciate offsetting losses from the drop in the long position's value.Moving against Molecular Stock
| 0.57 | ZTS | Zoetis Inc | PairCorr |
| 0.48 | HLN | Haleon plc | PairCorr |
| 0.37 | ELAN | Elanco Animal Health | PairCorr |
| 0.35 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.31 | TAK | Takeda Pharmaceutical | PairCorr |
The ability to find closely correlated positions to Molecular Partners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Molecular Partners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Molecular Partners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Molecular Partners AG to buy it.
The correlation of Molecular Partners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Molecular Partners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Molecular Partners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Molecular Partners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Molecular Partners Piotroski F Score and Molecular Partners Altman Z Score analysis. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.14) | Revenue Per Share 0.182 | Quarterly Revenue Growth (0.73) | Return On Assets (0.21) | Return On Equity (0.37) |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.